Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback